PRMT5-MTA inhibitor as well as preparation method and application thereof

By designing a specific structure of PRMT5-MTA inhibitor, the problem of insufficient enzyme inhibition activity and selectivity in the prior art is solved, targeted inhibition of MTAP-deleted cancer cells and retention of normal cell activity, and excellent drug abortion Kinetic properties and oral absorption effect, suitable for the treatment of PRMT5-related diseases.

CN118908939APending Publication Date: 2024-11-08SUN YAT SEN UNIV +2
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410890987.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-04
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The enzyme inhibitory activity and selectivity of existing PRMT5-MTA inhibitors are poor, making it difficult to effectively target MTAP-deleted cancer cells. At the same time, it has an inhibitory effect on the PRMT5 activity of normal cells, resulting in dose-limiting toxicity.

Method used

A PRMT5-MTA inhibitor with a specific structure was designed to enhance the binding ability of the PRMT5-MTA complex by introducing a merging structure, achieving targeted inhibition of MTAP-deleted cancer cells while retaining PRMT5 in normal cells. activity, excellent pharmacokinetic properties and oral absorption effect.

Benefits of technology

Targeted inhibition of PRMT5 activity in MTAP-deleted cancer cells is achieved, reducing the impact on normal cells, has excellent enzyme inhibitory activity and selectivity, and has excellent pharmacokinetic properties and oral absorption effect, which is suitable for prevention and treat PRMT5-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908939A_ABST
    Figure CN118908939A_ABST
Patent Text Reader

Abstract

The invention relates to a PRMT5-MTA inhibitor, the PRMT5-MTA inhibitor has a structure as shown in a formula (I): # imgabs0, the PRMT5-MTA inhibitor has relatively strong selectivity and inhibition effect on a PRMT5-MTA compound, can realize targeted inhibition of the activity of PRMT5 in MTAP-deficient cancer cells while retaining the activity of PRMT5 in normal cells, and in addition, the PRMT5-MTA inhibitor also has excellent pharmacokinetic properties, so that the PRMT5-MTA inhibitor can be applied to preparation of medicines for preventing and treating cancer cells with MTAP-deficient cancer cells. The compound has an excellent oral absorption effect and can be used for preventing and / or treating PRMT5 related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and more specifically, to a PRMT5-MTA inhibitor and a preparation method and application thereof. Background Art

[0002] As an epigenetic enzyme, PRMT5 can regulate a variety of physiological processes, such as cell signaling, mRNA splicing, transcriptional regulation, DNA repair, cell differentiation and apoptosis. A large number of studies have shown that PRMT5 is a cancer-related gene, and its overexpression plays a key role in the occurrence, development and poor prognosis of many tumors, including lung cancer, breast cancer, leukemia, melanoma and glioblastoma, and has different occurrence mechanisms in different tumors.

[0003] The first generation of PRMT5 inhibitors are mainly divided into two categories: SAM competitive inhibitors and SAM non-competitive inhibitors. As the research deepened, researchers found that the first generation of inhibitors also inhibited PRMT5 in normal cells, resulting in dose-limiting toxicity (such as thrombocytopenia, anemia, and neutropenia). In 2016, multiple independent research teams reported that in MTAP-deficient cancers, loss of the phosphorylation methylthioadenosine (MTAP) gene led to increased dependence on PRMT5. The MTAP gene is adjacent to the most commonly deleted tumor suppressor gene CDKN2A in human cancers and is often co-deleted with it. MTAP is a key enzyme in the methionine and adenine recycling pathway. Homozygous gene deletion causes MTAP-deficient (MTAP-del) cells to accumulate methylthioadenosine (MTA). MTA competes with the activated cofactor S-adenosyl-L-methionine (SAM), resulting in a decrease in PRMT5 activity and sensitizing MTAP-del cells to further loss of PRMT5 activity.

[0004] At present, there have been reports on PRMT5-MTA inhibitors for MTAP-deficient cancer cells. For example, TNG908 has entered the clinical evaluation stage, but its enzyme inhibition activity and selectivity still need to be further improved to meet more clinical needs. Summary of the invention

[0005] The primary purpose of the present invention is to overcome the problems of poor PRMT5-MTA enzyme inhibition activity and selectivity of the above-mentioned existing PRMT5-MTA inhibitors, and to provide a PRMT5-MTA inhibitor. The PRMT5-MTA inhibitor has strong selectivity and inhibitory effect on the PRMT5-MTA complex, can achieve targeted inhibition of PRMT5 activity in MTAP-deficient cancer cells, while retaining PRMT5 activity in normal cells. In addition, the PRMT5-MTA inhibitor also has excellent pharmacokinetic properties and excellent oral absorption effect, and can be used to prevent and / or treat PRMT5-related diseases.

[0006] A further object of the present invention is to provide a method for preparing the above PRMT5-MTA inhibitor.

[0007] A further object of the present invention is to provide use of the above-mentioned PRMT5-MTA inhibitor or a pharmaceutically acceptable salt or solvate thereof in the preparation of a PRMT5 inhibitor.

[0008] A further object of the present invention is to provide the use of the above-mentioned PRMT5-MTA inhibitor or a pharmaceutically acceptable salt or solvate thereof in the preparation of a drug for preventing and treating a disease associated with PRMT5.

[0009] A further object of the present invention is to provide a drug comprising the above-mentioned PRMT5-MTA inhibitor or a pharmaceutically acceptable salt or solvate thereof.

[0010] The above-mentioned object of the present invention is achieved by the following technical solutions:

[0011] A PRMT5-MTA inhibitor having a structure as shown in formula (I):

[0012]

[0013] Wherein, X is -N or -CH;

[0014] R 1 is selected from halogen, -CN, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C3-C9 cycloalkyl, C3-C9 cycloalkylalkyl, 3-10 membered heterocyclyl, 3-10 membered heterocyclylalkyl, C6-C 10 Arylalkyl, 5-10 membered heteroarylalkyl, -OR a 、-N(R a )2, -C(=O)R a 、-C(=O)OR a 、-NR a C(O)R a 、-NR a C(=O)ORa 、-C(=O)N(R a )2, -C(=O)N(OR a )(R a )、-OC(=O)N(R a )2, -S(=O)R a 、-S(=O)2R a 、-SR a 、-NR a S(=O)2R a or -S(=O)2N(R a )2, the C1-C6 heteroalkyl, 3-10 membered heterocyclyl, 3-10 membered heterocyclylalkyl or 5-10 membered heteroarylalkyl contains 1-2 heteroatoms, and the heteroatoms are independently selected from N, O or S;

[0015] R 2 is selected from -H, -D, halogen, -CN, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C3-C9 cycloalkyl, C3-C9 cycloalkylalkyl, 3-10 membered heterocyclyl, 3-10 membered heterocyclylalkyl, C6-C 10 Arylalkyl, 5-10 membered heteroarylalkyl, -OR a 、-N(R a )2, -C(=O)R a 、-C(=O)OR a 、-NR a C(=O)R a 、-NR a C(=O)OR a 、-C(=O)N(R a )2, -OC(=O)N(R a )2, -S(=O)R a 、-S(=O)2R a 、-SR a 、-NR a S(=O)2R a or -S(=O)2N(R a )2, the C1-C6 heteroalkyl, 3-10 membered heterocyclyl, 3-10 membered heterocyclylalkyl or 5-10 membered heteroarylalkyl contains 1-2 heteroatoms, and the heteroatoms are independently selected from N, O or S;

[0016] R a Selected from -H, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C9 cycloalkyl, C3-C9 cycloalkylalkyl, 3-7 membered heterocyclyl, 3-7 membered heterocyclylalkyl, C6-C 10 Aryl, C6-C 10Arylalkyl, 5-6 membered heteroaryl or 5-6 membered heteroarylalkyl, the C1-C6 alkyl, C1-C6 heteroalkyl, C3-C9 cycloalkyl, C3-C9 cycloalkylalkyl, 3-7 membered heterocyclyl, 3-7 membered heterocyclylalkyl, C6-C 10 Aryl, C6-C 10 Arylalkyl, 5-6 membered heteroaryl or 5-6 membered heteroarylalkyl is independently substituted by 0, 1, 2 or 3 R b Substitution, the C1-C6 heteroalkyl, 3-7 membered heterocyclyl, 3-7 membered heterocyclylalkyl, 5-6 membered heteroaryl or 5-6 membered heteroarylalkyl contains 1-2 heteroatoms, and the heteroatoms are independently selected from N, O or S;

[0017] R b Selected from -H, halogen, C1-C6 alkyl or C3-C9 cycloalkyl;

[0018] Or, R 2 Together with the carbon atoms to which they are attached, they form C4-C 10 Cycloalkyl, 4-10 membered heterocyclic group, C6-C 10 Aryl or 5-10 membered heteroaryl, the C4-C 10 Cycloalkyl, 4-10 membered heterocyclic group, C6-C 10 The aryl or 5-10 membered heteroaryl is independently substituted by 1, 2, 3, 4 or 5 R c Substitution, the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group contains 1-2 heteroatoms, and the heteroatoms are independently selected from N, O or S;

[0019] R c Selected from -H, halogen, -CF3, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C9 cycloalkyl, C3-C9 cycloalkylalkyl, 3-7 membered heterocyclyl, 3-7 membered heterocyclylalkyl, C6-C 10 Aryl, C6-C 10 Arylalkyl, 5-6-membered heteroaryl or 5-6-membered heteroarylalkyl, wherein the C1-C6 heteroalkyl, 3-7-membered heterocyclyl, 3-7-membered heterocyclylalkyl, 5-6-membered heteroaryl or 5-6-membered heteroarylalkyl contains 1-2 heteroatoms, and the heteroatoms are independently selected from N, O or S;

[0020] Ring A is selected from C3-C 10 Cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl or C6-C 10 Aryl, the C3-C 10 Cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl or C6-C 10 The aryl groups are independently substituted by 1, 2, 3 or 4 R dSubstitution, the 3-10 membered heterocyclic group or the 5-10 membered heteroaryl group contains 1-2 heteroatoms, and the heteroatoms are independently selected from N, O or S;

[0021] R d Selected from -H, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C3-C9 cycloalkyl, 3-10 membered heterocyclyl, C6-C 10 Aryl, 5-10 membered heteroaryl, -OR b 、N(R b )2, -C(=O)OR b 、-NR b C(=O)R b 、-NR b C(=O)OR b 、-C(=O)N(R b )2, -OC(=O)N(R b )2, -S(=O)R b 、-S(=O)2R b 、-SR b 、-NR b S(=O)2R b or -S(=O)2N(R b )2, the C1-C6 heteroalkyl, 3-10 membered heterocyclyl or 5-10 membered heteroaryl contains 1-2 heteroatoms, and the heteroatoms are independently selected from N, O or S;

[0022] Ring B is selected from C3-C 10 Cycloalkyl or 5-10 membered heterocyclic group, the C3-C 10 The cycloalkyl or 5-10 membered heterocyclic group is independently substituted by 1, 2, 3 or 4 R e Substitution, the 5-10 membered heterocyclic group contains 1-2 heteroatoms, and the heteroatoms are independently selected from N, O or S;

[0023] R e Selected from -H, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C3-C9 cycloalkyl, 3-10 membered heterocyclyl, C6-C 10 Aryl, 5-10 membered heteroaryl, =O, -OR b 、N(R b )2, -C(=O)OR b 、-NR b C(=O)R b 、-NR b C(=O)OR b 、-C(=O)N(R b)2, -OC(=O)N(R b )2, -S(=O)R b 、-S(=O)2R b 、-SR b 、-NR b S(=O)2R b or -S(=O)2N(R b )2, the C1-C6 heteroalkyl, 3-10 membered heterocyclyl or 5-10 membered heteroaryl contains 1-2 heteroatoms, and the heteroatoms are independently selected from N, O or S.

[0024] The present invention As a fragment of the lead compound, and introducing a ring structure on its specific nitrogen, the PRMT5-MTA inhibitor of the present invention is obtained. The ring structure can extend to the hydrophobic pocket of the PRMT5-MTA complex, which is conducive to the binding of the PRMT5-MTA inhibitor to the PRMT5-MTA complex, thereby making the PRMT5-MTA inhibitor have a strong selectivity and inhibitory effect on the PRMT5-MTA complex, and can achieve targeted inhibition of PRMT5 activity in MTAP-deficient cancer cells while retaining PRMT5 activity in normal cells. In addition, the PRMT5-MTA inhibitor also has excellent pharmacokinetic properties, has excellent oral absorption effect, and can be used to prevent and / or treat PRMT5-related diseases.

[0025] Preferably, the R 1 is selected from halogen, -CN, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C3-C9 cycloalkyl, C3-C9 cycloalkylalkyl, 3-10 membered heterocyclyl, 3-10 membered heterocyclylalkyl, C6-C 10 Arylalkyl, 5-10 membered heteroarylalkyl, -OR a 、-N(R a )2, -C(=O)R a 、-C(=O)OR a 、-NR a C(O)R a 、-NR a C(=O)OR a 、-C(=O)N(R a )2、-C(=O)N(OR a )(R a ) or -OC(=O)N(R a )2.

[0026] More preferably, the R 1 Selected from C1-C6 alkyl.

[0027] More preferably, the R 1 Selected from methyl or ethyl.

[0028] Preferably, the R 2 is selected from -H, -D, halogen, -CN, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C3-C9 cycloalkyl, C3-C9 cycloalkylalkyl, 3-10 membered heterocyclyl, 3-10 membered heterocyclylalkyl, C6-C 10 Arylalkyl, 5-10 membered heteroarylalkyl, -OR a 、-N(R a )2, -C(=O)R a 、-C(=O)OR a 、-NR a C(=O)R a 、-NR a C(=O)OR a 、-C(=O)N(R a )2 or -OC(=O)N(R a ).

[0029] More preferably, the R 2 Selected from -H, -D, halogen or C1-C6 haloalkyl.

[0030] More preferably, the R 2 Selected from halogen or -CF3.

[0031] Preferably, the R d Selected from -H or halogen.

[0032] Preferably, when the ring B is a 5- to 10-membered heterocyclic group, the heteroatom in the 5- to 10-membered heterocyclic group may be shared with the ring A or not.

[0033] Preferably, the R e Selected from -H.

[0034] Preferably, the ring A is selected from 5-10 membered heteroaryl or C6-C 10 Aryl.

[0035] More preferably, the ring A is selected from a 5-6 membered heteroaryl group or a phenyl group.

[0036] More preferably, the R d Selected from -H or -F.

[0037] Preferably, the ring B is selected from a C5-C6 cycloalkyl group or a 5-6 membered heterocyclic group.

[0038] More preferably, when the ring B is a 5-6 membered heterocyclic group, the heteroatom in the 5-6 membered heterocyclic group may be shared with the ring A or not.

[0039] Preferably, when X is N, ring A is phenyl, and ring B is cyclohexane, the inhibitory activity, selectivity and pharmacokinetic properties of the PRMT5-MTA inhibitor of the present invention are better.

[0040] Preferably, the 5-6 membered heteroaryl or 5-10 membered heteroaryl is independently selected from furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl.

[0041] Preferably, the C3-C9 cycloalkyl or C3-C 10 The cycloalkyl groups are independently selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane or cycloheptane.

[0042] Preferably, the C4-C 10 The cycloalkyl group is selected from cyclobutane, cyclopentane, cyclohexane or cycloheptane.

[0043] Preferably, the 3-7 membered heterocyclyl, 3-10 membered heterocyclyl, 4-10 membered heterocyclyl or 5-10 membered heterocyclyl is independently selected from morpholinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, pyranyl, pyrazolyl, homopiperazinyl or tetrahydropyridinyl.

[0044] Preferably, the PRMT5-MTA inhibitor is any one of the structures shown in numbers P1 to P13:

[0045]

[0046]

[0047] The PRMT5-MTA inhibitors of the present invention may include one or more asymmetric centers, and therefore may exist in a variety of stereoisomeric forms. For example, the PRMT5-MTA inhibitors of the present invention may be individual enantiomers, diastereomers, or geometric isomers (e.g., cis and trans isomers); or may be in the form of a mixture of stereoisomers, including a racemic mixture and a mixture enriched in one or more stereoisomers. Isomers may be separated from the mixture by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers may be prepared by asymmetric synthesis.

[0048] The PRMT5-MTA inhibitors of the present invention may also exist as tautomers. The PRMT5-MTA inhibitors that exist in different tautomeric forms are not limited to any specific tautomers, but are intended to cover all tautomeric forms.

[0049] The preparation method of the above PRMT5-MTA inhibitor comprises the following steps:

[0050] S1. Compound 1-1 and compound 1-2 undergo condensation reaction to generate compound 1-3;

[0051]

[0052] S2. Compound 1-3 is deprotected from Boc to obtain the PRMT5-MTA inhibitor;

[0053] Among them, R 1 , R 2 The definitions of Ring A and Ring B are the same as above.

[0054] Specifically, the reaction process of the above preparation method is as follows:

[0055]

[0056] Preferably, the condensation reaction in step S1 is carried out in the presence of a condensing agent and an organic base.

[0057] More preferably, the condensing agent is at least one of HATU, EDCI, CDI or PyBop.

[0058] More preferably, the organic base is at least one of triethylamine or DIPEA.

[0059] Preferably, the Boc removal reaction in step S2 is carried out in the presence of an acid.

[0060] More preferably, the acid in step S2 is at least one of hydrochloric acid or trifluoroacetic acid.

[0061] The use of the above-mentioned PRMT5-MTA inhibitor or a pharmaceutically acceptable salt or solvate thereof in the preparation of a PRMT5 inhibitor is also within the protection scope of the present invention.

[0062] The use of the above-mentioned PRMT5-MTA inhibitor or a pharmaceutically acceptable salt or solvate thereof in the preparation of a drug for preventing and / or treating a disease associated with PRMT5 is also within the protection scope of the present invention.

[0063] Preferably, the drug is a drug for preventing and / or treating tumors.

[0064] The above-mentioned PRMT5-MTA inhibitor has a significant anti-tumor effect, can inhibit tumor growth and metastasis, and promote cell apoptosis.

[0065] Specifically, representative pharmaceutically acceptable salts include hydrochloride, hydrobromide, nitrate, methylnitrate, sulfate, bisulfate, aminosulfate, phosphate, acetate, glycolate, phenylacetate, propionate, butyrate, isobutyrate, valerate, maleate, hydroxymaleate, acrylate, fumarate, malate, tartrate, citrate, salicylate, para-aminosalicylate, glycolate, lactate, heptanoate, phthalate, oxalate, succinate, benzoate , o-acetoxybenzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, mandelate, tannate, formate, stearate, ascorbate, palmitate, oleate, pyruvate, bishydroxynaphthoate, malonate, laurate, glutarate, glutamate, propionate lauryl sulfate, methanesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, benzenesulfonate, p-aminobenzenesulfonate, p-toluenesulfonate (toluenesulfonate) or naphthalene-2-sulfonate.

[0066] Preferably, the tumor is at least one of a cancer or a benign tumor.

[0067] More preferably, the cancer includes hematopoietic cancer (such as acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, follicular lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone B-cell lymphoma, primary mediastinal B-cell lymphoma, Burkitt's lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, primary central nervous system lymphoma, precursor T-lymphoblastic lymphoma, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy-type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, anaplastic large cell lymphoma, myeloproliferative disease, multiple myeloma heavy chain disease), hemangioblastoma, inflammatory myofibroblastic tumor, immune cell amyloidosis, kidney cancer (such as Wilms tumor, renal cell carcinoma), liver cancer (such as hepatocellular carcinoma, malignant hepatocellular carcinoma), lung cancer (such as bronchial cancer, small cell lung cancer, non-small cell lung cancer), leiomyosarcoma, mastocytosis (such as systemic mastocytosis), myelodysplastic syndrome, mesothelioma, acoustic neuroma, adrenal cancer, anal cancer, angiosarcoma (such as lymphangiosarcoma, lymphangioendothelioma, hemangioma), appendix cancer, benign monoclonal gamma disease, bile duct cancer, bladder cancer, brain cancer (such as meningioma), glioma (such as astrocytoma, oligodendroglioma, medulloblastoma), carcinoid tumor, cervical cancer (such as cervical adenocarcinoma ), choriocarcinoma, chordoma, craniopharyngioma, colorectal cancer (e.g., colon cancer, rectal cancer, large intestine adenocarcinoma), epithelial cancer, ependymoma, endothelial sarcoma (e.g., Kaposi sarcoma, multiple idiopathic hemorrhagic sarcoma), endometrial cancer (e.g., uterine cancer, uterine sarcoma), esophageal cancer (e.g., esophageal adenocarcinoma, Barrett's adenocarcinoma), Ewing's sarcoma, eye cancer (e.g., intraocular melanoma, retinoblastoma), hypereosinophilia, gallbladder cancer, stomach cancer (e.g., gastric adenocarcinoma), gastrointestinal stromal tumors, head and neck or oral cancer.

[0068] A drug comprising the above-mentioned PRMT5-MTA inhibitor or a pharmaceutically acceptable salt or solvate thereof.

[0069] Compared with the prior art, the present invention has the following beneficial effects:

[0070] The PRMT5-MTA inhibitor provided by the present invention has strong selectivity and inhibitory effect on the PRMT5-MTA complex, and can achieve targeted inhibition of PRMT5 activity in MTAP-deficient cancer cells while retaining PRMT5 activity in normal cells. In addition, the PRMT5-MTA inhibitor also has excellent pharmacokinetic properties and excellent oral absorption effect, and can be used to prevent and / or treat PRMT5-related diseases. DETAILED DESCRIPTION

[0071] In order to more clearly and completely describe the technical solution of the present invention, the present invention is further described in detail through specific embodiments below. It should be understood that the specific embodiments described herein are only used to explain the present invention, and are not used to limit the present invention. Various changes can be made within the scope of the rights of the present invention.

[0072] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0073] Abbreviations: MeOH = methanol; EA = ethyl acetate; DCM = dichloromethane; DMF = N,N-dimethylformamide; THF = tetrahydrofuran; SOCl2 = thionyl chloride; DIEA = diisopropylethylamine; TEA = triethylamine; DMAP = 4-dimethylaminopyridine; (Boc)2O = di-tert-butyl dicarbonate; Pd(Dppf)Cl2 = 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride.

[0074] The intermediates used in the embodiments and comparative examples of the present invention and their preparation methods are as follows:

[0075] Intermediate 1: 2-((6-(bis(tert-butoxycarbonyl)amino)-5-methylpyridin-3-yl)amino)-2-oxoacetic acid

[0076] The preparation method of the intermediate 1 is as follows:

[0077]

[0078] a) 3-methyl-2-amino-5-nitropyridine (5 g, 32.7 mmol) was added to DMF (100 mL), and DMAP (798 mg, 6.54 mmol) was added. (Boc)2O (18.8 mL, 81.7 mmol) was added at 0°C, and the mixture was reacted at 25°C for 2 h. After the reaction was completed, the mixture was diluted with water and extracted with EA. The combined organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained solid was purified by silica gel flash column chromatography to obtain white solid compound 1a (10.1 g) with a yield of 87.5%. 1 H NMR(500MHz,Chloroform-d)δ9.19(d,J=2.4Hz,1H),8.40(d,J=2.7Hz,1H),2.38(s,3H),1.43(d,J=1.8Hz,18H).LCMS:m / z(M+H + ):354.37.

[0079] b) Compound 1a (5 g, 14.2 mmol) was dissolved in a mixed solvent of MeOH (25 mL) and THF (25 mL), followed by the addition of Pd / C (500 mg, 10%). The mixture was stirred at 25°C under H2 atmosphere for 16 h, and the filtrate was filtered and concentrated to give a yellow solid compound 1b (2.94 g) with a yield of 64.1%. 1 H NMR(500MHz,Chloroform-d)δ7.77(d,J=2.8Hz,1H),6.86(d,J=2.9Hz,1H),3.77(s,2H),2.12(s,3H),1.40(s,18H).LCMS:m / z(M+H + ):324.40.

[0080] c) Compound 1b (2.94 g, 9.1 mmol) was added to a DCM solution (20 mL) at 0°C, and TEA (3.79 mL, 27.3 mmol) was added. Methyl 2-chloro-2-oxoacetate (820 μL, 9.1 mmol) was slowly added dropwise to the reaction system and stirred at 25°C for 2 h. After the reaction was completed, the reaction was quenched with water, and the aqueous phase was extracted with DCM. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel rapid column chromatography to obtain a yellow oily compound 1c (2.4 g) with a yield of 64.5%. 1 H NMR(500MHz,Chloroform-d)δ8.97(s,1H),8.45(d,J=2.7Hz,1H),8.20(d,J=2.6Hz,1H),4.00(s,3H),2.26(s,3H),1.41(s,18H).LCMS:m / z(M+H + ):409.45.

[0081] d) Compound 1c (2.33 g, 5.70 mmol) was dissolved in THF (15 mL) and stirred in an ice bath. Subsequently, lithium hydroxide (205 mg, 8.55 mol) was dissolved in water (10 mL) and slowly added dropwise to the reaction solution. The mixture was stirred at 25° C. for 2 h and acidified to pH = 4 with 1N hydrochloric acid. The residue was filtered to generate white solid intermediate 1 (1.54 g) with a yield of 68.4%. 1 HNMR (400MHz, DMSO-d6) δ11.01(s,1H),8.64(d,J=2.6Hz,1H),8.14(d,J=2.5Hz,1H),2.14(s,3H),1.36(d,J=3.4Hz,18H).LCMS:m / z(M+H + ):396.42.

[0082] Intermediate 2: 2-((6-(bis(tert-butoxycarbonyl)amino)-5-ethylpyridin-3-yl)amino)-2-oxoacetic acid

[0083] The preparation method of the intermediate 2 is as follows:

[0084]

[0085] e) The 3-methyl-2-amino-5-nitropyridine in step a) of the preparation method of intermediate 1 was replaced by 2-amino-3-bromo-5-nitropyridine, and the other steps were the same as step a) of the preparation method of intermediate 1 to obtain a white solid compound 2a with a yield of 80.2%. 1 H NMR(400MHz,Chloroform-d)δ9.28(q,J=2.1Hz,1H),8.75(q,J=2.1Hz,1H),1.40(s,18H).LCMS:m / z(M+H + ):419.25.

[0086] f) Compound 2a (500 mg, 1.20 mmol) and potassium carbonate (825 mg, 5.98 mmol) were added to a mixed solvent of 1,4-dioxane (7.5 mL) and water (1.9 mL) and stirred, followed by the addition of potassium vinyl trifluoroborate (192 mg, 1.44 mol). Pd(Dppf)Cl2 (44 mg, 0.06 mmol) was added under a nitrogen atmosphere. The reaction mixture was stirred at 80° C. under a nitrogen atmosphere for 16 h, the solvent was removed in vacuo, and the compound 2b (220 mg) was purified by silica gel column chromatography with a yield of 50%. 1 HNMR(400MHz,Chloroform-d)δ9.22(d,J=2.9Hz,1H),8.65(d,J=3.0Hz,1H),6.74(dd,J=1 7.5,11.1Hz,1H),6.13–5.92(m,1H),5.76–5.56(m,1H),1.53–1.24(m,18H).LCMS:m / z(M+H + ):366.35.

[0087] g) Compound 1a in step b) of the preparation method of intermediate 1 was replaced by compound 2b, and the other steps were the same as step b) of the preparation method of intermediate 1 to obtain white solid compound 2c with a yield of 75.5%. 1H NMR(400MHz,Chloroform-d)δ7.72(d,J=3.0Hz,1H),6.83(d,J=3.1Hz,1H),3.68(s,2H) ,2.50–2.34(m,2H),1.33(d,J=2.6Hz,18H),1.12(dt,J=8.9,4.4Hz,3H).LCMS:m / z(M+H + ):338.43.

[0088] h) Compound 1b in step c) of the preparation method of intermediate 1 was replaced by compound 2c, and the other steps were the same as step c) of the preparation method of intermediate 1 to obtain yellow oily compound 2d with a yield of 72.2%. 1 H NMR(500MHz,Chloroform-d)δ9.01(s,1H),8.43(d,J=2.6Hz,1H),8.15(d,J=2.6Hz,1H) ,3.92(s,3H),2.52(q,J=7.6Hz,2H),1.33(s,18H),1.18(t,J=7.5Hz,3H).LCMS:m / z(M+H + ):423.48.

[0089] i) Compound 1c in step d) of the preparation method of intermediate 1 was replaced by compound 2d, and the other steps were the same as step d) of the preparation method of intermediate 1 to obtain white solid intermediate 2 with a yield of 82.1%. 1 H NMR(500MHz,DMSO-d6)δ11.01(s,1H),8.68(d,J=2.5Hz,1H),8.18(d,J=2.6Hz, 1H),2.45(q,J=7.5Hz,2H),1.35(s,18H),1.16(t,J=7.6Hz,3H).LCMS:m / z(M+H + ):410.44.

[0090] Intermediate 3: (R)-5,6,7,8-Tetrahydroquinolin-8-amine

[0091] The preparation method of the intermediate 3 is as follows:

[0092]

[0093] j) 6,7-dihydro-5H-quinolin-8-one (1 g, 6.8 mmol) was dissolved in THF (10 mL), and (R)-2-methylpropane-2-sulfenamide (1.23 g, 10.2 mmol) and Ti(OEt)4 (3.1 g, 13.6 mmol) were added in sequence. The mixture was reacted at 65°C for 16 h under nitrogen protection. The reaction liquid temperature was then lowered to -45°C, NaBH4 was slowly added, and after stirring for 10 min, the temperature was slowly raised to 25°C and reacted for 2 h. After the reaction was completed, THF was removed, EA and water were added for extraction, the organic solution was washed with a saturated sodium chloride solution, then dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography to obtain a colorless oily compound 3a (402 mg) with a yield of 23.5%. 1 HNMR(400MHz,Chloroform-d)δ8.40(d,J=4.3Hz,1H),7.41(d,J=7.7Hz,1H),7.11(dd,J=7.7,4.8Hz,1H),5.06(s,1H),4.51(dd,J=8.5,5.1Hz ,1H),2.81(t,J=5.1Hz,2H),2.47–2.30(m,1H),1.99(dd,J=10.6,4.7Hz,1H),1.80(tdd,J=11.6,9.0,2.6Hz,2H),1.26(s,9H).LCMS:m / z(M+H + ):253.77.

[0094] k) Compound 3a (180 mg, 0.714 mmol) of step j) was dissolved in methanol (4 mL), and 4N hydrochloric acid methanol solution (536 μL, 2.14 mmol) was slowly added dropwise under ice bath stirring, and then reacted at 25° C. for 3 h. After the reaction, the solvent was removed, saturated sodium bicarbonate solution was added to adjust the pH to 7, EA was added for extraction, and vacuum drying was performed to obtain intermediate 3 (88 mg), which was directly used in the next step. LCMS: m / z (M+H + ):149.18.

[0095] Intermediate 4:

[0096]

[0097] The 6,7-dihydro-5H-quinolin-8-one in step j) of the preparation method of intermediate 3 was replaced by 7,8-dihydro-6H-quinolin-5-one, and the other steps were the same as the preparation method of intermediate 3 to obtain intermediate 4. LCMS: m / z (M+H + ):149.19.

[0098] Intermediate 5:

[0099]

[0100] The 6,7-dihydro-5H-quinolin-8-one in step j) of the preparation method of intermediate 3 was replaced by 2,3-dihydro-1H-indene-1-one, and the other steps were the same as the preparation method of intermediate 3 to obtain intermediate 5. LCMS: m / z (M+H + ):134.21.

[0101] Intermediate 6:

[0102]

[0103] The 6,7-dihydro-5H-quinolin-8-one in step j) of the preparation method of intermediate 3 was replaced by 6,7-dihydroimidazo[1,2-a]pyridine-8(5H)-one, and the other steps were the same as the preparation method of intermediate 3 to obtain intermediate 6. LCMS: m / z (M+H + ):138.33.

[0104] Intermediate 7:

[0105]

[0106] The 6,7-dihydro-5H-quinolin-8-one in step j) of the preparation method of intermediate 3 was replaced by 5H-pyrrolo[1,2-a]imidazol-7(6H)-one, and the other steps were the same as the preparation method of intermediate 3 to obtain intermediate 7. LCMS: m / z (M+H + ):124.25.

[0107] Intermediate 8:

[0108]

[0109] The 6,7-dihydro-5H-quinolin-8-one in step j) of the preparation method of intermediate 3 was replaced by 4-dihydrochromone, and the other steps were the same as the preparation method of intermediate 3 to obtain intermediate 8. LCMS: m / z (M+H + ):150.20.

[0110] Intermediate 9:

[0111]

[0112] The 6,7-dihydro-5H-quinolin-8-one in step j) of the preparation method of intermediate 3 was replaced by 6,7-dihydro-4(5H)-benzofuranone, and the other steps were the same as the preparation method of intermediate 3 to obtain intermediate 9. LCMS: m / z (M+H + ):138.19.

[0113] Intermediate 10: (R)-N-((5-bromopyridin-2-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine

[0114] The preparation method of the intermediate 10 is as follows:

[0115]

[0116] 5-Bromopyridine-2-carboxaldehyde (126 mg, 0.676 mmol) was dissolved in ethanol (5 mL), and then intermediate 3 (100 mg, 0.676 mmol) was added and stirred at 25°C for 4 h. The reaction system was cooled to 0°C, and sodium borohydride (51 mg, 1.35 mmol) was slowly added and reacted at 25°C for 2 h. After the reaction was completed, water was added to quench the reaction, extracted with EA, and the organic phase was concentrated. The residue was purified by silica gel column chromatography to obtain colorless oily intermediate 10 (162 mg) with a yield of 75.4%. 1 H NMR(400MHz,Chloroform-d)δ8.62(d,J=2.4Hz,1H),8.41(d,J=4.2Hz,1H),7.76(dd,J=8.3,2.4Hz,1H),7.38(d,J=8.6Hz,2H),7. 11–7.06(m,1H),4.06(s,2H),3.87(dd,J=7.7,5.2Hz,1H),2.87–2.72(m,2H),2.08–1.96(m,2H),1.86–1.69(m,2H).LCMS:m / z(M+H + ):319.22.

[0117] Intermediate 11:

[0118]

[0119] Intermediate 11 is obtained by replacing Intermediate 3 in the preparation method of Intermediate 10 with Intermediate 4 and carrying out other steps in the same manner as the preparation method of Intermediate 10. 1 H NMR (400MHz, Chloroform-d) δ8.61(d,J=2.3Hz,1H),8.40(d,J=5.0Hz,1H),7.77(t,J=7.9Hz,2H),7.33(d,J=8.2Hz,1H),7.10(dd,J =7.8,4.7Hz,1H),4.09–3.90(m,2H),3.86(t,J=5.3Hz,1H),3.05–2.85(m,2H),2.01–1.95(m,2H),1.92–1.80(m,2H).LCMS:m / z(M+H + ):319.22.

[0120] Intermediate 12:

[0121]

[0122] The 5-bromopyridine-2-carboxaldehyde in the preparation method of intermediate 10 is replaced by 4-bromobenzaldehyde, and intermediate 3 is replaced by intermediate 5. The other steps are the same as the preparation method of intermediate 10 to obtain intermediate 12. 1 H NMR (400MHz, Chloroform-d) δ7.48–7.40(m,2H),7.39–7.32(m,1H),7.27(d,J=8.1Hz,2H),7.26–7.14(m,3H),4.26(t,J=6. 6Hz,1H),3.85(d,J=5.3Hz,2H),3.06–2.94(m,1H),2.87–2.74(m,1H),2.47–2.35(m,1H),1.91–1.78(m,1H).LCMS:m / z(M+H + ):303.20.

[0123] Intermediate 13:

[0124]

[0125] The 5-bromopyridine-2-carboxaldehyde in the preparation method of intermediate 10 is replaced by 4-bromobenzaldehyde, and intermediate 3 is replaced by (R)-1,2,3,4-tetrahydro-1-naphthylamine. The other steps are the same as the preparation method of intermediate 10 to obtain intermediate 13. 1 H NMR(400MHz,Chloroform-d)δ7.44(d,J=8.3Hz,2H),7.38–7.31(m,2H),7.28(d,J=8.1Hz,2H),7.18–7.11(m,2H),7.12–7.04(m,1H), 3.84(d,J=19.7Hz,2H),3.82–3.75(m,2H),2.88–2.70(m,2H),2.03–1.94(m,1H),1.95–1.83(m,2H),1.80–1.68(m,1H).LCMS:m / z(M+H + ):317.23.

[0126] Intermediate 14:

[0127]

[0128] Intermediate 14 is obtained by replacing Intermediate 3 in the preparation method of Intermediate 10 with (R)-1,2,3,4-tetrahydro-1-naphthylamine and carrying out other steps in the same manner as the preparation method of Intermediate 10. 1 H NMR(500MHz,Chloroform-d)δ8.61(d,J=2.4Hz,1H),7.77(dd,J=8.3,2.4Hz,1 H),7.42–7.36(m,2H),7.36(d,J=8.3Hz,1H),7.19–7.13(m,2H),7.12–7.06(m, 1H),4.04–3.92(m,2H),3.82(t,J=5.0Hz,1H),2.88–2.79(m,1H),2.79–2.68( m,1H),2.06–1.97(m,1H),1.95–1.88(m,2H),1.79–1.70(m,2H).LCMS:m / z(M+H + ):318.24.

[0129] Intermediate 15:

[0130]

[0131] The 5-bromopyridine-2-carboxaldehyde in the preparation method of intermediate 10 is replaced by 5-trifluoromethylpyridine-2-carboxaldehyde, and intermediate 3 is replaced by (R)-1,2,3,4-tetrahydro-1-naphthylamine. The other steps are the same as the preparation method of intermediate 10 to obtain intermediate 15. 1 H NMR(400MHz,Chloroform-d)δ8.99–8.68(m,1H),7.91(dd,J=8.2,2.4Hz,1H),7.62(d,J=8.2Hz,1H),7.58–7.39(m,1H),7.24–7.16(m,2H),7.14– 7.06(m,1H),4.24–4.04(m,2H),3.87(t,J=5.0Hz,1H),2.91–2.75(m,2H) ,2.10–2.02(m,1H),1.99–1.94(m,2H),1.83–1.67(m,1H).LCMS:m / z(M+H + ):307.34.

[0132] Intermediate 16:

[0133]

[0134] Intermediate 16 is obtained by replacing Intermediate 3 in the preparation method of Intermediate 10 with (R)-6-fluoro-1,2,3,4-tetrahydronaphthalene-1-amine and carrying out the other steps in the same manner as the preparation method of Intermediate 10.1 H NMR(400MHz,Chloroform-d)δ8.61(d,J=2.4Hz,1H),7.77(dd,J=8.3,2.4Hz,1H),7.45–7.28(m,2H),6.92–6.72(m,2 H),4.04–3.86(m,2H),3.78(t,J=4.9Hz,1H),2.88–2.64(m,2H),1.99–1.88(m,2H),1.80–1.72(m,2H).LCMS:m / z(M+H + ):336.23.

[0135] Intermediate 17:

[0136]

[0137] Intermediate 17 is obtained by replacing 5-bromopyridine-2-carboxaldehyde in the preparation method of intermediate 10 with 4-bromobenzaldehyde, and replacing intermediate 3 with intermediate 7. The other steps are the same as the preparation method of intermediate 10. 1 H NMR(400MHz,Chloroform-d)δ7.43(d,J=8.0Hz,2H),7.27(d,J=8.1Hz,2H),7.09(s,1H),6.86(s,1H),4.18(dd ,J=7.7,4.6Hz,1H),4.15–4.04(m,1H),4.05–3.80(m,3H),2.93–2.77(m,1H),2.44–2.32(m,1H).LCMS:m / z(M+H + ):294.17.

[0138] Intermediate 18:

[0139]

[0140] Intermediate 18 is obtained by replacing 5-bromopyridine-2-carboxaldehyde in the preparation method of intermediate 10 with 4-bromobenzaldehyde, and replacing intermediate 3 with intermediate 6. The other steps are the same as the preparation method of intermediate 10. 1 H NMR(400MHz,Chloroform-d)δ7.36(d,J=8.2Hz,2H),7.21(d,J=8.3Hz,3H),6.95(s,1H),6.72 (s,1H),3.88–3.85(m,3H),2.82(s,2H),2.18–2.00(m,2H),1.87–1.71(m,2H).LCMS:m / z(M+H + ):307.21.

[0141] Intermediate 19:

[0142]

[0143] Intermediate 19 is obtained by replacing Intermediate 3 in the preparation method of Intermediate 10 with Intermediate 8 and following the same other steps as the preparation method of Intermediate 10. 1 H NMR(400MHz,Chloroform-d)δ8.55(d,J=2.4Hz,1H),8.09(dd,J=4.1,1.9Hz,1H),7.70(dd,J=8.3,2.4Hz,1H),7.30(s,1H),7.09–6.99(m,2 H),4.38–4.25(m,1H),4.21–4.08(m,1H),4.01(d,J=3.0Hz,2H),3.90(t,J=5.6Hz,1H),2.18–2.07(m,1H),2.06–1.94(m,1H).LCMS:m / z(M+H + ):320.21.

[0144] Intermediate 20:

[0145]

[0146] Intermediate 20 is obtained by replacing Intermediate 3 in the preparation method of Intermediate 10 with Intermediate 9 and following the same other steps as the preparation method of Intermediate 10. 1 H NMR(500MHz,Chloroform-d)δ8.56(d,J=2.4Hz,1H),7.75(dd,J=8.3,2.3Hz,1H),7.26(d,J=8.3Hz,1H),7.13(d,J=8.3Hz,1H),6 .34(d,J=1.9Hz,1H),4.66(s,2H),3.74(t,J=4.5Hz,1H),2.68–2.42(m,2H),2.06–1.90(m,2H),1.76–1.65(m,2H).LCMS:m / z(M+H + ):308.18.

[0147] Intermediate 21:

[0148]

[0149] The 5-bromopyridine-2-carboxaldehyde in the preparation method of intermediate 10 is replaced by 5-trifluoromethylpyridine-2-carboxaldehyde, and intermediate 3 is replaced by 4-aminotetrahydropyran. The other steps are the same as the preparation method of intermediate 10 to obtain intermediate 21. 1HNMR(500MHz,Chloroform-d)δ8.82(d,J=2.3Hz,1H),7.89(dd,J=8.3,2.3Hz,1H),7.49(d,J=8.1Hz,1H),4.04(s,2H),3.99(dt,J=11.6,3. 5Hz,2H),3.40(td,J=11.7,2.2Hz,2H),2.74(tt,J=10.6,4.1Hz,1H),1.93–1.86(m,3H),1.49(dtd,J=13.1,11.0,4.4Hz,2H).LCMS:m / z(M+H + ):261.26.

[0150] Intermediate 22:

[0151]

[0152] The 5-bromopyridine-2-carboxaldehyde in the preparation method of intermediate 10 is replaced by 5-trifluoromethylpyridine-2-carboxaldehyde, and intermediate 3 is replaced by 2,2,2-trifluoroethylamine. The other steps are the same as the preparation method of intermediate 10 to obtain intermediate 22. 1 HNMR(400MHz,Chloroform-d)δ8.83(s,1H),7.91(d,J=8.3Hz,1H),7.48(d,J=8.2Hz,1H),4.11(s,2H),3.26(q,J=9.5Hz,2H),2.26(s,1H).LCMS:m / z(M+H + ):259.15.

[0153] Example 1

[0154] This example provides a PRMT5-MTA inhibitor (denoted as compound P1), the structural formula of which is as follows:

[0155] Compound P1:

[0156] The preparation method of the PRMT5-MTA inhibitor comprises the following steps:

[0157] 1) Intermediate 1 (39.3 mg, 0.099 mmol) was dissolved in DMF (5 mL), and HATU (37.6 mg, 0.099 mmol), DIEA (32.7 μL, 0.198 mmol), and intermediate 10 (21 mg, 0.066 mmol) were added in sequence, and stirred at 25°C for 16 h. After the reaction was completed, EA and water were added for extraction, and the organic solution was washed with a saturated sodium chloride solution, then dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography to obtain a yellow oily compound P1a (33 mg). LCMS: m / z (M+H + ):696.62.

[0158] 2) Compound P1a (33 mg, 0.047 mmol) of step 1) was dissolved in DCM (4 mL), stirred at 0°C and trifluoroacetic acid (0.4 mL, 5.4 mmol) was slowly added dropwise, and then stirred and reacted for 5 h at 0°C. After the reaction was completed, the solvent was removed, saturated sodium bicarbonate was added to adjust the pH value to 8, and EA was used for extraction. The organic solution was washed with saturated sodium chloride solution, then dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography to obtain white solid compound P1 (20.5 mg) with a yield of 88.1%. 1 H NMR(500MHz,Chloroform-d)δ9.52(d,J=242.6Hz,1H),8.62–8.34(m,2H),7.94(dd,J=43.2,2 .5Hz,1H),7.84–7.67(m,2H),7.59–7.34(m,2H),7.20–7.07(m,1H),5.63(d,J=182.6Hz,1H),5 .33(d,J=17.3Hz,1H),4.92(d,J=16.2Hz,1H),4.43(d,J=11.2Hz,2H),3.87(d,J=16.2Hz,1H), 2.88–2.70(m,2H),2.31–2.22(m,1H),2.12(d,J=7.6Hz,3H),2.06–1.93(m,3H).LCMS:m / z(M+H + ):496.36.

[0159] The reaction process of the preparation method of the PRMT5-MTA inhibitor is as follows:

[0160]

[0161] Example 2

[0162] This example provides a PRMT5-MTA inhibitor (denoted as compound P2), the structural formula of which is as follows:

[0163] Compound P2:

[0164] The intermediate 10 in step 1) of the preparation method of Example 1 was replaced by the intermediate 11, and the other steps were the same as the preparation method of Example 1 to obtain compound P2. 1 H NMR(500MHz,Chloroform-d)δ9.02(d,J=18.5Hz,1H),8.48–8.08(m,2H),7.95(dd, J=33.6,2.5Hz,1H),7.73–7.36(m,3H),7.14–6.90(m,2H),6.57–5.75(m,1H),5.36– 4.68(m,1H),4.51–3.87(m,3H),2.94–2.82(m,2H),2.26–2.11(m,1H),2.05(d,J=1 2.9Hz,3H),1.98–1.92(m,1H),1.86–1.79(m,1H),1.64–1.54(m,1H).LCMS:m / z(M+H + ):496.39.

[0165] Example 3

[0166] This example provides a PRMT5-MTA inhibitor (denoted as compound P3), the structural formula of which is as follows:

[0167] Compound P3:

[0168] The intermediate 10 in step 1) of the preparation method of Example 1 was replaced by intermediate 12, and the other steps were basically the same as Example 1 to obtain compound P3. 1 HNMR(400MHz,Chloroform-d)δ9.27(d,J=19.7Hz,1H),8.02(dd,J=37.3,2.5Hz,1H),7.68 (dd,J=57.8,2.5Hz,1H),7.36(dd,J=10.2,8.3Hz,2H),7.25–7.09(m,4H),6.98(dd,J=20. 2,8.1Hz,2H),6.75–5.96(m,1H),5.02(dd,J=270.9,16.0Hz,1H),4.50–3.99(m,3H),2.92 –2.76(m,2H),2.59–2.32(m,1H),2.11(d,J=12.1Hz,3H),2.02–1.95(m,1H).LCMS:m / z(M+H + ):480.35.

[0169] Example 4

[0170] This example provides a PRMT5-MTA inhibitor (denoted as compound P4), the structural formula of which is as follows:

[0171] Compound P4:

[0172] The intermediate 10 in step 1) of the preparation method of Example 1 was replaced by intermediate 13, and the other steps were basically the same as Example 1 to obtain compound P4. 1 HNMR(500MHz,Chloroform-d)δ9.20(d,J=25.2Hz,1H),8.53(dd,J=10.3,2.3Hz,1H),8.02(dd,J=37.7,2.5Hz,1H),7.84–7.55(m,2H),7.18–7.01(m,4H),6 .51–5.89(m,1H),5.53–4.82(m,1H),4.59–3.96(m,3H),2.91–2.66(m,2H),2. 31(d,J=4.9Hz,1H),2.12(d,J=13.9Hz,3H),1.99–1.66(m,5H).LCMS:m / z(M+H + ):495.40.

[0173] Example 5

[0174] This example provides a PRMT5-MTA inhibitor (denoted as compound P5), the structural formula of which is as follows:

[0175] Compound P5:

[0176] The intermediate 10 in step 1) of the preparation method of Example 1 was replaced by intermediate 14, and the other steps were basically the same as Example 1 to obtain compound P5. 1 HNMR(400MHz,Chloroform-d)δ9.18(d,J=39.6Hz,1H),8.01(dd,J=37.7,2.5Hz,1H),7.65(dd,J=71.6,2.5Hz,1H),7.49–7.31(m,2H),7.21–6.99(m,6H), 6.52–5.70(m,1H),5.41–4.73(m,1H),4.48–3.80(m,3H),2.82–2.63(m,2H), 2.36–2.26(m,1H),2.11(d,J=10.0Hz,3H),1.89–1.71(m,3H).LCMS:m / z(M+H +):494.41.

[0177] Example 6

[0178] This example provides a PRMT5-MTA inhibitor (denoted as compound P6), the structural formula of which is as follows:

[0179] Compound P6:

[0180] The intermediate 10 in step 1) of the preparation method of Example 1 was replaced by intermediate 15, and the other steps were basically the same as Example 1 to obtain compound P6. 1 HNMR(500MHz,Chloroform-d)δ9.26(d,J=12.5Hz,1H),8.67(dd,J=12.7,2.3Hz,1H),7.95(dd,J= 35.1,2.5Hz,1H),7.84–7.44(m,2H),7.30(d,J=8.3Hz,1H),7.14–6.99(m,4H),6.15(ddd,J=243.1 ,10.3,5.8Hz,1H),5.18(dd,J=346.0,17.2Hz,1H),4.58–4.01(m,3H),2.68(dd,J=8.3,4.5Hz,2H ),2.34–2.10(m,1H),2.03(d,J=21.2Hz,3H),1.89–1.78(m,1H),1.76–1.40(m,2H).LCMS:m / z(M+H + ):484.50.

[0181] Example 7

[0182] This example provides a PRMT5-MTA inhibitor (denoted as compound P7), the structural formula of which is as follows:

[0183] Compound P7:

[0184] The intermediate 10 in step 1) of the preparation method of Example 1 was replaced by intermediate 16, and the other steps were basically the same as Example 1 to obtain compound P7. 1HNMR(400MHz,Chloroform-d)δ9.23(d,J=17.6Hz,1H),8.53(dd,J=6.6,2.3Hz,1H),8.02(dd,J=32.2,2.5Hz,1H),7.80–7.59(m,2H),7.19–7.01(m,2H),6. 89–6.77(m,2H),6.46–5.81(m,1H),5.45–4.79(m,1H),4.52–3.98(m,3H),2. 73(q,J=5.3Hz,2H),2.12(d,J=11.5Hz,5H),1.77–1.51(m,2H).LCMS:m / z(M+H + ):513.37.

[0185] Example 8

[0186] This example provides a PRMT5-MTA inhibitor (denoted as compound P8), the structural formula of which is as follows:

[0187] Compound P8:

[0188] The intermediate 10 in step 1) of the preparation method of Example 1 was replaced by intermediate 17, and the other steps were basically the same as Example 1 to obtain compound P8. 1 HNMR(500MHz,Chloroform-d)δ9.32(d,J=26.1Hz,1H),7.99(dd,J=38.5,2.5Hz,1H),7.6 3(dd,J=34.0,2.5Hz,1H),7.32(dd,J=15.7,8.3Hz,2H),7.15–6.96(m,2H),6.97–6.71(m ,2H),6.12–5.27(m,2H),5.26–5.11(m,1H),4.78–3.88(m,3H),3.75–3.63(m,1H),3.38– 3.25(m,1H),3.06–2.76(m,1H),2.28–2.18(m,1H),2.06(d,J=7.8Hz,4H).LCMS:m / z(M+H + ):470.35.

[0189] Example 9

[0190] This example provides a PRMT5-MTA inhibitor (denoted as compound P9), the structural formula of which is as follows:

[0191] Compound P9:

[0192] The intermediate 10 in step 1) of the preparation method of Example 1 was replaced by intermediate 18, and the other steps were basically the same as Example 1 to obtain compound P9. 1 HNMR(500MHz,Chloroform-d)δ9.82(d,J=124.5Hz,1H),8.08–7.80(m,1H),7.72–7.52( m,1H),7.44–7.31(m,2H),7.16(d,J=8.1Hz,1H),7.12–6.91(m,2H),6.85–6.70(m,1H),5 .68(s,1H),5.04–4.85(m,1H),4.37(s,2H),3.81(dtd,J=74.9,12.0,5.8Hz,2H),3.36– 3.32(m,1H),2.37–2.20(m,1H),2.02(d,J=3.5Hz,3H),1.91–1.55(m,3H).LCMS:m / z(M+H + ):484.36.

[0193] Example 10

[0194] This example provides a PRMT5-MTA inhibitor (denoted as compound P10), the structural formula of which is as follows:

[0195] Compound P10:

[0196] The intermediate 10 in step 1) of the preparation method of Example 1 was replaced by intermediate 19, and the other steps were basically the same as Example 1 to obtain compound P10. 1 H NMR(500MHz,Chloroform-d)δ9.17(s,1H),8.54(dd,J=16.1,2.4Hz,1H),8.02(dd,J=44.6,2.5Hz,1H),7.81–7.51(m,2H),7.21–6.93(m,3H),6.94– 6.72(m,2H),6.67–5.97(m,1H),5.45–4.80(m,1H),4.61–3.97(m,5H),2. 39–2.26(m,1H),2.13(d,J=17.2Hz,3H),2.07–1.92(m,1H).LCMS:m / z(M+H + ):497.35.

[0197] Embodiment 11

[0198] This example provides a PRMT5-MTA inhibitor (denoted as compound P11), the structural formula of which is as follows:

[0199] Compound P11:

[0200] The intermediate 10 in step 1) of the preparation method of Example 1 was replaced by the intermediate 20, and the other steps were basically the same as those of Example 1 to obtain compound P11. 1 H NMR(400MHz,Chloroform-d)δ9.06(d,J=48.3Hz,1H),8.62–8.34(m,1H),7.96(d,J=37.9Hz,1H),7.81–7.42(m,2H),7. 17–6.85(m,2H),6.28–5.64(m,2H),5.31–4.19(m,4H),2.49(s,2H),2.06(d,J=16.8Hz,3H),1.89(s,4H).LCMS:m / z(M+H + ):485.33.

[0201] Example 12

[0202] This example provides a PRMT5-MTA inhibitor (denoted as compound P12), the structural formula of which is as follows:

[0203] Compound P12:

[0204] In step 1) of the preparation method of Example 1, intermediate 1 is replaced by intermediate 2, intermediate 10 is replaced by intermediate 15, and the other steps are basically the same as those of Example 1 to obtain compound P12. 1 H NMR(500MHz,Chloroform-d)δ9.33(d,J=20.4Hz,1H),8.74(dd,J=11.4,2.3Hz,1H),8.07(dd,J=36.0,2.5 Hz,1H),7.82(ddd,J=24.4,8.2,2.3Hz,1H),7.64(dd,J=100.3,2.5Hz,1H),7.37(d,J=8.3Hz,1H),7.21–7 .10(m,4H),6.22(ddd,J=244.6,10.4,6.0Hz,1H),5.62–4.90(m,1H),4.63–4.08(m,3H),2.75(dd,J=8.3, 4.6Hz,2H),2.47–2.39(m,2H),2.03–1.87(m,2H),1.81–1.46(m,2H),1.21(t,J=7.5Hz,3H).LCMS:m / z(M+H + ):498.53.

[0205] Embodiment 13

[0206] This example provides a PRMT5-MTA inhibitor (denoted as compound P13), the structural formula of which is as follows:

[0207] Compound P13:

[0208] In step 1) of the preparation method of Example 1, intermediate 1 is replaced by intermediate 2, intermediate 10 is replaced by intermediate 14, and the other steps are basically the same as in Example 1 to obtain compound P13. 1 H NMR(500MHz,Chloroform-d)δ9.33(d,J=42.0Hz,1H),8.52(dd,J=6.4,2.3Hz,1H),8.05(dd, J=37.7,2.5Hz,1H),7.81–7.53(m,2H),7.20–6.99(m,5H),6.16(ddd,J=251.4,10.5,6.3Hz, 1H),5.14(dd,J=318.8,16.8Hz,1H),4.55–3.94(m,3H),2.85–2.69(m,2H),2.49–2.38(m,2H ),2.36–2.15(m,1H),2.03–1.92(m,1H),1.83–1.50(m,2H),1.26–1.21(m,3H).LCMS:m / z(M+H + ):509.43.

[0209] Comparative Example 1

[0210] This comparative example provides a comparative PRMT5-MTA inhibitor (denoted as compound X), the structural formula of which is as follows:

[0211] Compound X:

[0212] The intermediate 10 in step 1) of the preparation method of Example 1 was replaced by intermediate 21, and the other steps were basically the same as in Example 1 to obtain compound X. 1HNMR(400MHz,Chloroform-d)δ9.13(d,J=31.6Hz,1H),8.79(d,J=10.0Hz,1H),8. 02(d,J=30.7Hz,1H),7.88(t,J=8.0Hz,1H),7.67(d,J=50.5Hz,1H),7.42(dd,J=29 .2,8.3Hz,1H),5.37–4.67(m,3H),4.44(d,J=19.0Hz,2H),4.05–3.89(m,2H),3.4 7(q,J=11.8,9.7Hz,2H),2.13(d,J=25.5Hz,3H),1.80–1.55(m,4H).LCMS:m / z(M+H + ):438.40.

[0213] Comparative Example 2

[0214] This comparative example provides a comparative PRMT5-MTA inhibitor (denoted as compound Y), the structural formula of which is as follows:

[0215] Compound Y:

[0216] The intermediate 10 in step 1) of the preparation method of Example 1 was replaced by intermediate 22, and the other steps were basically the same as Example 1 to obtain compound Y. 1 HNMR(500MHz,Chloroform-d)δ9.26(d,J=34.6Hz,1H),8.81(dd,J=21.1,2.3Hz,1H) ,8.15(dd,J=15.1,2.5Hz,1H),7.94(dt,J=8.3,2.8Hz,1H),7.64(dd,J=47.0,2.5Hz ,1H),7.45(dd,J=10.9,8.2Hz,1H),5.96(d,J=99.2Hz,2H),5.47(s,1H),5.00(q,J= 8.6Hz,1H),4.91(s,1H),4.24(q,J=8.8Hz,1H),2.18(d,J=8.9Hz,3H).LCMS:m / z(M+H + ):436.30.Performance test

[0217] 1. Activity inhibition test of PRMT5-MTA by the PRMT5-MTA inhibitor of the present invention

[0218] Detection method: AlphaLISA

[0219] Test principle:

[0220] AlphaLISA technology relies on the interaction of Alpha donor beads and acceptor beads. When the biological reaction brings the donor beads and acceptor beads into close proximity, the laser stimulates a cascade reaction, resulting in a greatly amplified signal. Specifically,

[0221] Under 680nm laser irradiation, the photosensitizer on the donor microbeads converts oxygen in the surrounding environment into more active monomeric oxygen. Monomeric oxygen diffuses to the acceptor microbeads, producing a series of chemiluminescent reactions, and finally transfers energy to europium with an emission wavelength of 615nm. When there is no specific interaction between biological molecules, monomeric oxygen cannot diffuse to the acceptor microbeads, and no signal will be generated. In this experiment, arginine methyltransferase PRMT5 can methylate the substrate H4R3 site, and the inhibition of PRMT5 by the compound can be achieved by detecting the methylation degree of the H4R3 site. H4 biotinylated substrate binds to the donor microbeads. The acceptor microbeads coupled with the specific anti-H4R3 methylation antibody also bind to the methylated site. If the methylation degree is high, there are more acceptor microbeads bound to the substrate, and the donor microbeads and acceptor microbeads can interact with each other, thereby generating a 615nm light signal. The strength of the light signal is related to the degree of methylation of the H4R3 site, which can reflect the inhibitory effect of the compound on PRMT5.

[0222] Test method:

[0223] 1. Dilute PRMT5 enzyme, S-adenosylmethionine (SAM), methylthioadenosine (MTA), inhibitors and biotinylated histone H4 peptide (1-21) in assay buffer;

[0224] 2. Add the following reagents to the 384-well white microplate in sequence: 2.5 μL inhibitor (4X) or assay buffer, 5 μL enzyme / MTA mixed solution (2X), incubate at 37°C for 10 min, and then add 2.5 μL biotinylated histone H4 peptide (1-21) / SAM mixed solution (4X);

[0225] 3. Seal the microplate with the top cover and incubate at 25°C for 150 min;

[0226] 4. Prepare 1X Epigenetics Buffer 1;

[0227] 5. Prepare 100 μg / mL anti-H4R3 methylation antibody-coupled receptor microbead solution with 1X Epigenetics Buffer 1, with a final concentration of 20 μg / mL;

[0228] 6. Add 5 μL of anti-H4R3 methylation antibody coupled to receptor microbead solution (5X), seal and incubate for 60 min;

[0229] 7. Prepare 50 μg / mL streptavidin donor microbead solution with 1X Epigenetics Buffer 1 to a final concentration of 20 μg / mL;

[0230] 8. Add 10 μL of streptavidin donor microbead solution, seal and incubate in dark for 30 min;

[0231] 9. Use EnVision to read the data. Set up two sets of wells for each group of experiments and a blank control group.

[0232] 10. The inhibition rate (%) of the compound on enzyme activity was calculated using the following formula:

[0233] Inhibition rate (%) = {[(positive control signal value - blank control signal value) - (test compound signal value - blank control signal value)] / (positive control signal value - blank control signal value)}

[0234] The corresponding IC was calculated based on the inhibition rate of each concentration. 50 .

[0235] The test results are shown in Table 1, where IC 50 <0.01μΜ for AA, 0.01μΜ <IC 50 <0.1μΜ for A, 0.1μΜ <IC 50 <1μΜ for B, 1μΜ <IC 50 For C.

[0236] Among them, the structural formula of compound TNG908 is The same experiment was carried out according to Experiment 1 of the present invention.

[0237] Table 1 Results of inhibition of PRMT5-MTA enzyme activity by different PRMT5-MTA inhibitors

[0238]

[0239]

[0240] In Table 1:

[0241] The results of PRMT5-MTA enzyme activity inhibition of compound P in each example were A or AA, indicating that the PRMT5-MTA inhibitor of the present invention has excellent enzyme inhibitory activity.

[0242] The compound X of Comparative Example 1 or the compound Y of Comparative Example 2 does not introduce a cyclic structure at the specific nitrogen, and the enzyme inhibition activity of the PRMT5-MTA inhibitor is poor.

[0243] In addition, compared with the positive control TNG908, the results of the PRMT5-MTA enzyme activity inhibition of the compound P in each example are the same level (A) or better (AA), wherein, when the results of the PRMT5-MTA enzyme activity inhibition are the same level, the IC value of the PRMT5-MTA inhibitor of the present invention is 50 The value was lower than the IC of the positive control TNG908 50 value.

[0244] 2. Human Colon Cancer HCT116 Cell Proliferation Inhibition Experiment

[0245] Purpose of the experiment: To evaluate the effects of test compounds P1, P2, P4, P6, P7, P10, P11 and P13 on the proliferation of human colon cancer HCT116 cells.

[0246] Test cell lines:

[0247] HCT116(△MTAP#wt), HCT116(△MTAP#1), HCT116(△MTAP#2)

[0248] Observation index: Inhibition rate of compound on each cell proliferation

[0249] Detection method: CCK-8 cell counting kit (Dojindo)

[0250] Duration of action: 6 days

[0251] Reagents, consumables and instruments: The water used in the experiment was distilled water produced by Sinopharm Group; all reagents used were purchased from Sinopharm Chemical Reagent Co., Ltd.; the full-wavelength microplate reader used for plate reading was a product of Molecular Devices.

[0252] Compound preparation: Centrifuge the compound at 12000g for 5 minutes, add DMSO to prepare a 10mM stock solution, vortex evenly and sonicate for 10 minutes before use, store at -40°C (compounds with special storage requirements shall be modified according to specific circumstances). When testing, dilute the compound from the stock solution with physiological saline to an appropriate concentration (DMSO concentration in the system shall not exceed 0.5%).

[0253] Test method (specific method to be selected):

[0254] The inhibitory effect of the compound on the proliferation of HCT116 (△MTAP#wt), HCT116 (△MTAP#1), and HCT116 (△MTAP#2) cells was detected by CCK-8 cell counting kit (Dojindo). The specific steps are as follows: HCT116 (△MTAP#wt), HCT116 (△MTAP#1), and HCT116 (△MTAP#2) cells in the logarithmic growth phase were inoculated into 96-well culture plates at an appropriate density, 190 μL per well, and cultured overnight. Different concentrations of the compound were added for 6 days, and a solvent control group (negative control) was set. After the compound acted on the cells for 6 days, the effect of the compound on cell proliferation was detected by CCK-8 cell counting kit (Life-iLab, China). 20 μL of CCK-8 reagent was added to each well, placed in a 37°C incubator for 2 to 4 hours, and read with a full-wavelength microplate reader SpectraMax 190, and the measurement wavelength was 450nm.

[0255] The inhibition rate (%) of the compound on tumor cell growth was calculated using the following formula:

[0256] Inhibition rate (%) = (OD control well - OD drug well) / OD control well × 100%

[0257] The corresponding IC was calculated based on the inhibition rate of each concentration. 50 .

[0258] The test results are shown in Table 2, where IC 50 <0.01μΜ for AA, 0.01μΜ <IC 50 <0.1μΜ for A, 0.1μΜ <IC 50 <1μΜ for B, 1μΜ <IC 50 For C.

[0259] Among them, the compound TNG908 was subjected to the same test according to the second test of the present invention.

[0260] Table 2 Antiproliferative effects of different PRMT5-MTA inhibitors on different cell lines

[0261]

[0262] In Table 2:

[0263] The results of the inhibition of the compound P in each example on the MTAP-deficient HCT116 cells were A or AA, and the results of the inhibition on the wild-type HCT116 cells were B or C, indicating that the PRMT5-MTA inhibitor of the present invention has a significant anti-proliferative effect on the MTAP-deficient HCT116 cells at the cellular level, and has a weaker inhibitory effect on the wild-type HCT116 cells. At the same time, the IC of the compound P in each example on HTC116-MTAP wt 50 Value divided by the IC of HTC116-MTAP del 50 The values ​​show that the selectivity of the PRMT5-MTA inhibitors of the present invention is greater than 10 times (among which, the selectivity of compound P6 and compound P13 is greater than 100 times), indicating that the PRMT5-MTA inhibitors of the present invention have excellent selectivity.

[0264] In addition, compared with the positive control TNG908, the compound P of each example showed better inhibition results on MTAP-deficient HCT116 cells (A or AA), and the selectivity of the PRMT5-MTA inhibitor of the present invention was better than that of the positive control TNG908.

[0265] 3. Pharmacokinetic evaluation test in mice

[0266] Animal information: 1) Species / breed: CD-1 mouse; 2) Sex / number: male / 12; 3) Body weight: 20-23 g.

[0267] Feeding method: standard sawtooth diet, no restriction on drinking water, fasting started 12h before administration and remained fasting for 2h after administration.

[0268] Rearing environment: The animal room environment was controlled (target conditions: temperature 18-29°C, relative humidity 30-70%), temperature and relative humidity were monitored daily, and an electronic time-controlled lighting system was used to provide a 12-h light and 12-h dark cycle.

[0269] Dosing Information:

[0270]

[0271] Sample collection:

[0272] CD-1 mice were intragastrically administered with 50 mg / kg of the test compound in a volume of 5 mL / kg. Blood was collected from the femoral vein of the mice at 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 8 h and 24 h after administration. 20 μL of blood was placed in a heparinized centrifuge tube and immediately centrifuged (11000 rpm) for 5 min to separate plasma samples.

[0273] CD-1 mice were intravenously injected with the test compound at 3 mg / kg in a volume of 5 mL / kg. At 0.05 h, 0.25 h, 0.75 h, 2 h, 4 h, 8 h and 24 h after administration, 20 μL of blood was collected from the femoral vein of the mice into a heparinized centrifuge tube and immediately centrifuged (11000 rpm) for 5 min to separate the plasma samples.

[0274] Sample processing and analysis:

[0275] 10 μL of plasma sample was taken into a 1.5 mL centrifuge tube pre-added with 100 μL of methanol / acetonitrile (v / v=1 / 1; containing 50 nM verapamil), vortexed for 5 min, centrifuged at 15000 rpm for 5 min, 20 μL of supernatant was taken to a 384-well plate, 20 μL of diluent (pure water) was added, and the plate was oscillated on an IKA oscillator for 20 min and then centrifuged at 4000 rpm for 10 min. The sample plate was subjected to LC-MS / MS analysis, and the pharmacokinetic parameters were calculated using Phoenix WinNonlin software. The pharmacokinetic parameters of the test compounds are shown in Table 3.

[0276] Table 3 Pharmacokinetic parameters in mice after administration of compounds P6 and P13

[0277]

[0278] As can be seen from Table 3, the PRMT5-MTA inhibitor of the present invention has excellent pharmacokinetic properties and excellent oral absorption effect, can be used to prevent and / or treat PRMT5-related diseases, and can bring about better therapeutic effects.

[0279] Obviously, the above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the embodiments here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. A PRMT5-MTA inhibitor, It is characterized in that Having the structure shown in formula (I): wherein X is selected from -N or -CH; R 1 Selected from halogen, -CN, C 1 -C 6 Alkyl, C 1 -C 6 Heteroalkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Haloalkoxy, C 3 -C 9 Cycloalkyl, C 3 -C 9 Cycloalkylalkyl, 3-10 membered heterocyclyl, 3-10 membered heterocyclylalkyl, C 6 -C 10 Arylalkyl, 5-10 membered heteroarylalkyl, -OR a 、-N(R a ) 2 、-C(=O)R a 、-C(=O)OR a 、-NR a C(O)R a 、-NR a C(=O)OR a 、-C(=O)N(R a ) 2 、-C(=O)N(OR a )(R a )、-OC(=O)N(R a ) 2 、-S(=O)R a 、-S(=O) 2 R a 、-SR a 、-NR a S(=O) 2 R a or -S(=O) 2 N(R a ) 2 , the C 1 -C 6 The heteroalkyl, 3-10 membered heterocyclyl, 3-10 membered heterocyclylalkyl or 5-10 membered heteroarylalkyl contains 1-2 heteroatoms, wherein the heteroatoms are independently selected from N, O or S; R 2 Selected from -H, -D, halogen, -CN, C 1 -C 6 Alkyl, C 1 -C 6 Heteroalkyl, C 1 -C 6 Haloalkyl, C 3 -C 9 Cycloalkyl, C 3 -C 9 Cycloalkylalkyl, 3-10 membered heterocyclyl, 3-10 membered heterocyclylalkyl, C 6 -C 10 Arylalkyl, 5-10 membered heteroarylalkyl, -OR a 、-N(R a ) 2 、-C(=O)R a 、-C(=O)OR a 、-NR a C(=O)R a 、-NR a C(=O)OR a 、-C(=O)N(R a ) 2 、-OC(=O)N(R a ) 2 、-S(=O)R a 、-S(=O) 2 R a 、-SR a 、-NR a S(=O) 2 R a or -S(=O) 2 N(R a ) 2 , the C 1 -C 6 The heteroalkyl, 3-10 membered heterocyclyl, 3-10 membered heterocyclylalkyl or 5-10 membered heteroarylalkyl contains 1-2 heteroatoms, wherein the heteroatoms are independently selected from N, O or S; R a Selected from -H, C 1 -C 6 Alkyl, C 1 -C 6 Heteroalkyl, C 3 -C 9 Cycloalkyl, C 3 -C 9 Cycloalkylalkyl, 3-7 membered heterocyclyl, 3-7 membered heterocyclylalkyl, C 6 -C 10 Aryl, C 6 -C 10 Arylalkyl, 5-6 membered heteroaryl or 5-6 membered heteroarylalkyl, the C 1 -C 6 Alkyl, C 1 -C 6 Heteroalkyl, C 3 -C 9 Cycloalkyl, C 3 -C 9 Cycloalkylalkyl, 3-7 membered heterocyclyl, 3-7 membered heterocyclylalkyl, C 6 -C 10 Aryl, C 6 -C 10 Arylalkyl, 5-6 membered heteroaryl or 5-6 membered heteroarylalkyl is independently substituted by 0, 1, 2 or 3 R b Substitute, the C 1 -C 6 The heteroalkyl, 3-7 membered heterocyclyl, 3-7 membered heterocyclylalkyl, 5-6 membered heteroaryl or 5-6 membered heteroarylalkyl contains 1-2 heteroatoms, wherein the heteroatoms are independently selected from N, O or S; R b Selected from -H, halogen, C 1 -C 6 Alkyl or C 3 -C 9 Cycloalkyl; Or, R 2 Together with the carbon atoms to which they are attached, they form C 4 -C 10 Cycloalkyl, 4-10 membered heterocyclic group, C 6 -C 10 Aryl or 5-10 membered heteroaryl, the C 4 -C 10 Cycloalkyl, 4-10 membered heterocyclic group, C 6 -C 10 The aryl or 5-10 membered heteroaryl is independently substituted by 1, 2, 3, 4 or 5 R c Substitution, the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group contains 1-2 heteroatoms, and the heteroatoms are independently selected from N, O or S; R c Selected from -H, halogen, -CF 3 , C 1 -C 6 Alkyl, C 1 -C 6 Heteroalkyl, C 3 -C 9 Cycloalkyl, C 3 -C 9 Cycloalkylalkyl, 3-7 membered heterocyclyl, 3-7 membered heterocyclylalkyl, C 6 -C 10 Aryl, C 6 -C 10 Arylalkyl, 5-6 membered heteroaryl or 5-6 membered heteroarylalkyl, the C 1 -C 6 The heteroalkyl, 3-7 membered heterocyclyl, 3-7 membered heterocyclylalkyl, 5-6 membered heteroaryl or 5-6 membered heteroarylalkyl contains 1-2 heteroatoms, wherein the heteroatoms are independently selected from N, O or S; Ring A is selected from C 3 -C 10 Cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl or C 6 -C 10 Aryl, the C 3 -C 10 Cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl or C 6 -C 10 The aryl groups are independently substituted by 1, 2, 3 or 4 R d Substitution, the 3-10 membered heterocyclic group or the 5-10 membered heteroaryl group contains 1-2 heteroatoms, and the heteroatoms are independently selected from N, O or S; R d Selected from -H, halogen, -CN, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 1 -C 6 Heteroalkyl, C 1 -C 6 Haloalkyl, C 3 -C 9 Cycloalkyl, 3-10 membered heterocyclic group, C 6 -C 10 Aryl, 5-10 membered heteroaryl, -OR b 、N(R b ) 2 、-C(=O)OR b 、-NR b C(=O)R b 、-NR b C(=O)OR b 、-C(=O)N(R b ) 2 、-OC(=O)N(R b ) 2 、-S(=O)R b 、-S(=O) 2 R b 、-SR b 、-NR b S(=O) 2 R b or -S(=O) 2 N(R b ) 2 , the C 1 -C 6 The heteroalkyl, 3-10 membered heterocyclyl or 5-10 membered heteroaryl contains 1-2 heteroatoms, and the heteroatoms are independently selected from N, O or S; Ring B is selected from C 3 -C 10 Cycloalkyl or 5-10 membered heterocyclic group, the C 3 -C 10 The cycloalkyl or 5-10 membered heterocyclic group is independently substituted by 1, 2, 3 or 4 R e Substitution, the 5-10 membered heterocyclic group contains 1-2 heteroatoms, and the heteroatoms are independently selected from N, O or S; R e Selected from -H, halogen, -CN, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 1 -C 6 Heteroalkyl, C 1 -C 6 Haloalkyl, C 3 -C 9 Cycloalkyl, 3-10 membered heterocyclic group, C 6 -C 10 Aryl, 5-10 membered heteroaryl, =O, -OR b 、N(R b ) 2 、-C(=O)OR b 、-NR b C(=O)R b 、-NR b C(=O)OR b 、-C(=O)N(R b ) 2 、-OC(=O)N(R b ) 2 、-S(=O)R b 、-S(=O) 2 R b 、-SR b 、-NR b S(=O) 2 R b or -S(=O) 2 N(R b ) 2 , the C 1 -C 6 The heteroalkyl, 3-10 membered heterocyclyl or 5-10 membered heteroaryl contains 1-2 heteroatoms, and the heteroatoms are independently selected from N, O or S.

2. The PRMT5-MTA inhibitor according to claim 1, It is characterized in that The ring A is selected from 5-10 membered heteroaryl or C 6 -C 10 Aryl.

3. The PRMT5-MTA inhibitor according to claim 1, It is characterized in that The ring B is selected from C 5 -C 6 Cycloalkyl or 5-6 membered heterocyclic group.

4. The PRMT5-MTA inhibitor according to claim 1, It is characterized in that The PRMT5-MTA inhibitor is any one of the structures shown in numbers P1 to P13:

5. The method for preparing the PRMT5-MTA inhibitor according to any one of claims 1 to 4, It is characterized in that The steps include: S1. Compound 1-1 and compound 1-2 undergo condensation reaction to generate compound 1-3; S2. Compound 1-3 is deprotected from Boc to obtain the PRMT5-MTA inhibitor.

6. The preparation method according to claim 5, It is characterized in that The condensation reaction in step S1 is carried out in the presence of a condensing agent and an organic base; the Boc protection removal reaction in step S2 is carried out in the presence of an acid.

7. Use of the PRMT5-MTA inhibitor or a pharmaceutically acceptable salt or solvate thereof according to any one of claims 1 to 4 in the preparation of a PRMT5 inhibitor.

8. Use of the PRMT5-MTA inhibitor or a pharmaceutically acceptable salt or solvate thereof according to any one of claims 1 to 4 in the preparation of a medicament for preventing and / or treating a disease associated with PRMT5.

9. The use according to claim 8, It is characterized in that The medicine is a medicine for preventing and / or treating tumors.

10. A drug, It is characterized in that It comprises the PRMT5-MTA inhibitor according to any one of claims 1 to 4 or a pharmaceutically acceptable salt or solvate thereof.

Citation Information

Cited By

  • PRMT5 inhibitors and uses thereof

    US12448388B2

  • PRMT5 inhibitors and uses thereof

    US12799113B2